THUMPD3-AS1 Is Correlated with Gastric Cancer and Regulates Cell Function through miR-1252-3p and CXCL17

Yuwei Tan,Liang Liu,Xuemei Zhang,Yu Xue,Jiafu Gao,Jintao Zhao,Nannan Chi,Yanli Zhu
DOI: https://doi.org/10.1615/CritRevEukaryotGeneExpr.2022042848
Abstract:The problem facing gastric cancer treatment is the uncontrollable prognosis. Long noncoding RNAs (lncRNAs) are the current hotspot for gastric cancer prognostic markers. This study was targeted at determining THUMPD3-AS1 expression in gastric cancer, and then exploring whether THUMPD3-AS1 is associated with prognosis and its role in cancerous cell function. THUMPD3-AS1 expression levels were quantified in human tissues and cell lines. The prognostic biomarker potential of THUMPD3-AS1 was evaluated by Kaplan-Meier and multivariate Cox regression analyses. The biological impact of THUMPD3-AS1 in gastric cancer cells was investigated by WST-1, Tran-swell, and reactive oxygen species (ROS) accumulation assay. The binding between THUMPD3-AS1, miR-1252-3p and CXCL17 was verified by luciferase reporter assay and RNA pulled down assay. THUMPD3-AS1 was significantly decreased in gastric cancer tissues and cells by comparing them with normal ones. THUMPD3-AS1 was related to the advanced TNM stage, lymphatic infiltration, and vascular infiltration. Downregulated THUMPD3-AS1 was associated with reduced 5-year overall survival. Overexpression of THUMPD3-AS1 inhibits proliferation, migration, invasion and ROS accumulation of gastric cancer cells by regulation of miR-1252-3p and CXCL17. THUMPD3-AS1 could be a potent prognostic symbol for patients with gastric cancer. THUMPD3-AS1 provides a therapeutic potential for gastric cancer.
What problem does this paper attempt to address?